Acalabrutinib for mantle cell lymphoma or chronic lymphocytic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is looking at how well acalabrutinib works in real-world patients who have mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). If you have one of these types of blood cancer and have not had certain other treatments, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with mantle cell lymphoma (MCL) who have had at least one prior treatment, OR chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have not yet been treated or have had at least one prior treatment.
- Your doctor thinks you are a good fit for acalabrutinib.
- You are willing to sign a consent form to participate.
- If you are able to have children, you must agree to use highly effective birth control during treatment and for at least 1 week after your last dose. You also need a negative pregnancy test within 7 days before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
This study looks at how acalabrutinib, a targeted therapy for chronic lymphocytic leukemia (CLL), works in real-life settings in Spain. It aims to see how well it helps people who are starting treatment for the first time or switching due to side effects.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.